Jounce Therapeutics, an early-stage biotech developing T-cell immuno-oncology therapies with Celgene, announced terms for its IPO on Tuesday.
The Cambridge, MA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Jounce Therapeutics would command a fully diluted market value of $468 million.
Jounce Therapeutics was founded in 2012 and has no material sales to date. It plans to list on the Nasdaq under the symbol JNCE. J.P. Morgan and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of January 30, 2017.
